These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
583 related articles for article (PubMed ID: 7692683)
1. Induction of feline leukaemia virus-neutralizing antibodies by immunization with synthetic peptides derived from the FeLV env gene. Weijer K; Pfauth A; van Herwijnen R; Jarrett O; Meloen RH; Tomee C; Osterhaus AD Vaccine; 1993; 11(9):946-56. PubMed ID: 7692683 [TBL] [Abstract][Full Text] [Related]
2. Antibodies neutralizing feline leukaemia virus (FeLV) in cats immunized with the transmembrane envelope protein p15E. Langhammer S; Hübner J; Kurth R; Denner J Immunology; 2006 Feb; 117(2):229-37. PubMed ID: 16423059 [TBL] [Abstract][Full Text] [Related]
3. Induction of protective immune response in cats by vaccination with feline leukemia virus iscom. Osterhaus A; Weijer K; Uytdehaag F; Jarrett O; Sundquist B; Morein B J Immunol; 1985 Jul; 135(1):591-6. PubMed ID: 2987351 [TBL] [Abstract][Full Text] [Related]
4. Feline leukemia virus envelope gp70 of subgroups B and C defined by monoclonal antibodies with cytotoxic and neutralizing functions. Grant CK; Ernisse BJ; Jarrett O; Jones FR J Immunol; 1983 Dec; 131(6):3042-8. PubMed ID: 6196410 [TBL] [Abstract][Full Text] [Related]
5. Virus neutralizing and enhancing epitopes characterized by synthetic oligopeptides derived from the feline leukaemia virus glycoprotein sequence. Nick S; Klaws J; Friebel K; Birr C; Hunsmann G; Bayer H J Gen Virol; 1990 Jan; 71 ( Pt 1)():77-83. PubMed ID: 1689371 [TBL] [Abstract][Full Text] [Related]
6. Development of a genetically engineered vaccine against feline leukemia virus infection. Kensil CR; Barrett C; Kushner N; Beltz G; Storey J; Patel U; Recchia J; Aubert A; Marciani D J Am Vet Med Assoc; 1991 Nov; 199(10):1423-7. PubMed ID: 1666096 [TBL] [Abstract][Full Text] [Related]
7. Feline leukemia virus envelope protein expression encoded by a recombinant vaccinia virus: apparent lack of immunogenicity in vaccinated animals. Gilbert JH; Pedersen NC; Nunberg JH Virus Res; 1987 Feb; 7(1):49-67. PubMed ID: 3031895 [TBL] [Abstract][Full Text] [Related]
8. Localization of neutralizing regions of the envelope gene of feline leukemia virus by using anti-synthetic peptide antibodies. Elder JH; McGee JS; Munson M; Houghten RA; Kloetzer W; Bittle JL; Grant CK J Virol; 1987 Jan; 61(1):8-15. PubMed ID: 2431166 [TBL] [Abstract][Full Text] [Related]
9. Control of feline leukaemia virus. Weijer K; Uytdehaag FG; Osterhaus AD Vet Immunol Immunopathol; 1989 May; 21(1):69-83. PubMed ID: 2549695 [TBL] [Abstract][Full Text] [Related]
10. Protection against feline leukemia virus infection by use of an inactivated virus vaccine. Hoover EA; Perigo NA; Quackenbush SL; Mathiason-DuBard CK; Overbaugh JM; Kloetzer WS; Elder JH; Mullins JI J Am Vet Med Assoc; 1991 Nov; 199(10):1392-401. PubMed ID: 1666090 [TBL] [Abstract][Full Text] [Related]
11. The feline oncornavirus-associated cell membrane antigen (FOCMA) is related to, but distinguishable from, FeLV-C gp70. Snyder HW; Singhal MC; Zuckerman EE; Jones FR; Hardy WD Virology; 1983 Dec; 131(2):315-27. PubMed ID: 6318434 [TBL] [Abstract][Full Text] [Related]
12. Feline oncornavirus-associated cell membrane antigen: a viral and not a cellularly coded transformation-specific antigen of cat lymphomas. Vedbrat SS; Rasheed S; Lutz H; Gonda MA; Ruscetti S; Gardner MB; Prensky W Virology; 1983 Jan; 124(2):445-61. PubMed ID: 6186079 [TBL] [Abstract][Full Text] [Related]
13. Formation and characterization of FeLV ISCOMs. Akerblom L; Strömstedt K; Hoglund S; Osterhaus A; Morein B Vaccine; 1989 Apr; 7(2):142-6. PubMed ID: 2750272 [TBL] [Abstract][Full Text] [Related]
14. Genetically-engineered subunit vaccine against feline leukaemia virus: protective immune response in cats. Marciani DJ; Kensil CR; Beltz GA; Hung CH; Cronier J; Aubert A Vaccine; 1991 Feb; 9(2):89-96. PubMed ID: 1647576 [TBL] [Abstract][Full Text] [Related]
15. Distinct mechanisms of neutralization by monoclonal antibodies specific for sites in the N-terminal or C-terminal domain of murine leukemia virus SU. Burkhart MD; Kayman SC; He Y; Pinter A J Virol; 2003 Apr; 77(7):3993-4003. PubMed ID: 12634359 [TBL] [Abstract][Full Text] [Related]
16. Vaccine-induced virus-neutralizing antibodies and cytotoxic T cells do not protect macaques from experimental infection with simian immunodeficiency virus SIVmac32H (J5). Hulskotte EG; Geretti AM; Siebelink KH; van Amerongen G; Cranage MP; Rud EW; Norley SG; de Vries P; Osterhaus AD J Virol; 1995 Oct; 69(10):6289-96. PubMed ID: 7666529 [TBL] [Abstract][Full Text] [Related]
17. Use of a subunit feline leukemia virus vaccine in exotic cats. Citino SB J Am Vet Med Assoc; 1988 Apr; 192(7):957-9. PubMed ID: 2835347 [TBL] [Abstract][Full Text] [Related]
18. Possible immunoenhancement of persistent viremia by feline leukemia virus envelope glycoprotein vaccines in challenge-exposure situations where whole inactivated virus vaccines were protective. Pedersen NC; Johnson L; Birch D; Theilen GH Vet Immunol Immunopathol; 1986 Feb; 11(2):123-48. PubMed ID: 3008409 [TBL] [Abstract][Full Text] [Related]
19. Influence of epitope polarity and adjuvants on the immunogenicity and efficacy of a synthetic peptide vaccine against Semliki Forest virus. Fernández IM; Snijders A; Benaissa-Trouw BJ; Harmsen M; Snippe H; Kraaijeveld CA J Virol; 1993 Oct; 67(10):5843-8. PubMed ID: 7690411 [TBL] [Abstract][Full Text] [Related]
20. Immunization with a single T helper cell epitope abrogates Friend virus-induced early erythroid proliferation and prevents late leukemia development. Miyazawa M; Fujisawa R; Ishihara C; Takei YA; Shimizu T; Uenishi H; Yamagishi H; Kuribayashi K J Immunol; 1995 Jul; 155(2):748-58. PubMed ID: 7541823 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]